Free Trial

SI-BONE, Inc. (NASDAQ:SIBN) Shares Bought by Granahan Investment Management LLC

SI-BONE logo with Medical background

Granahan Investment Management LLC raised its holdings in SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 13.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,286,450 shares of the company's stock after acquiring an additional 150,217 shares during the quarter. Granahan Investment Management LLC owned about 3.18% of SI-BONE worth $27,003,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of SIBN. First Light Asset Management LLC raised its holdings in shares of SI-BONE by 0.9% during the fourth quarter. First Light Asset Management LLC now owns 2,547,392 shares of the company's stock worth $53,470,000 after acquiring an additional 23,299 shares during the period. Kent Lake Capital LLC increased its stake in shares of SI-BONE by 33.3% during the 4th quarter. Kent Lake Capital LLC now owns 400,000 shares of the company's stock worth $8,396,000 after purchasing an additional 100,000 shares during the last quarter. Bellevue Group AG bought a new stake in shares of SI-BONE during the 4th quarter worth about $2,628,000. Campbell & CO Investment Adviser LLC boosted its holdings in shares of SI-BONE by 9.6% during the 4th quarter. Campbell & CO Investment Adviser LLC now owns 29,530 shares of the company's stock worth $620,000 after buying an additional 2,578 shares during the period. Finally, Alpha DNA Investment Management LLC bought a new stake in shares of SI-BONE during the 4th quarter worth about $556,000. 98.11% of the stock is owned by institutional investors.

SI-BONE Trading Down 3.5 %

Shares of NASDAQ:SIBN traded down $0.47 on Thursday, hitting $12.87. The company had a trading volume of 273,026 shares, compared to its average volume of 407,997. The firm's 50-day simple moving average is $14.59 and its two-hundred day simple moving average is $17.44. SI-BONE, Inc. has a 1 year low of $12.77 and a 1 year high of $29.51. The company has a quick ratio of 8.75, a current ratio of 9.76 and a debt-to-equity ratio of 0.22. The firm has a market capitalization of $530.31 million, a price-to-earnings ratio of -11.81 and a beta of 1.26.


SI-BONE (NASDAQ:SIBN - Get Free Report) last posted its earnings results on Monday, May 6th. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.02. The firm had revenue of $37.87 million during the quarter, compared to analysts' expectations of $36.45 million. SI-BONE had a negative net margin of 29.93% and a negative return on equity of 25.14%. Equities analysts anticipate that SI-BONE, Inc. will post -0.95 earnings per share for the current fiscal year.

Insider Buying and Selling at SI-BONE

In other news, insider Anthony J. Recupero sold 3,941 shares of SI-BONE stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $15.10, for a total value of $59,509.10. Following the completion of the sale, the insider now directly owns 247,592 shares in the company, valued at $3,738,639.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other SI-BONE news, insider Anthony J. Recupero sold 3,307 shares of the company's stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $15.50, for a total value of $51,258.50. Following the completion of the transaction, the insider now directly owns 252,453 shares in the company, valued at $3,913,021.50. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Anthony J. Recupero sold 3,941 shares of the company's stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $15.10, for a total transaction of $59,509.10. Following the completion of the transaction, the insider now owns 247,592 shares of the company's stock, valued at $3,738,639.20. The disclosure for this sale can be found here. In the last ninety days, insiders sold 14,379 shares of company stock worth $218,528. 5.40% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on SIBN shares. Morgan Stanley dropped their target price on shares of SI-BONE from $26.00 to $25.00 and set an "overweight" rating for the company in a research report on Tuesday, May 7th. Truist Financial reaffirmed a "buy" rating and issued a $24.00 price objective (down from $26.00) on shares of SI-BONE in a research report on Tuesday, February 27th. JMP Securities reaffirmed a "market outperform" rating and issued a $32.00 price objective on shares of SI-BONE in a research report on Tuesday, May 7th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 target price on shares of SI-BONE in a research note on Tuesday, February 27th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $27.00 target price on shares of SI-BONE in a report on Tuesday, May 7th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $27.29.

View Our Latest Report on SIBN

SI-BONE Profile

(Free Report)

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.

See Also

Institutional Ownership by Quarter for SI-BONE (NASDAQ:SIBN)

Should you invest $1,000 in SI-BONE right now?

Before you consider SI-BONE, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SI-BONE wasn't on the list.

While SI-BONE currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

CPI News Breakdown: Key Market Moves to Follow
Understanding Oversold Stocks
Inside Pelosi’s Latest Stock Moves

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines